Celgene Corporation Sees 2012 Total Revenue Guidance $5.4-5.6B vs $5.40B Est
Celgene Corporation (NASDAQ: CELG) today reviewed 2011 achievements and provided its outlook for 2012 at the JPMorgan 30th Annual Healthcare Conference.
In 2012, non-GAAP total revenue is targeted to increase approximately 15 percent year-over-year to a range of $5.4 to $5.6 billion. REVLIMID net product sales are expected to increase approximately 19 percent to a range of $3.75 to $3.85 billion. Non-GAAP diluted earnings per share (EPS) is targeted to increase approximately 25 percent to a range of $4.70 to $4.80 The EPS guidance assumes a constant share count from 2011 to 2012.
Preliminary 2011 unaudited results indicate that non-GAAP total revenue increased by approximately 34 percent to just over $4.8 billion. Non-GAAP diluted EPS increased approximately 36 percent to about $3.79 The Company will report its 2011 full-year financial results on Thursday, January 26, 2012.
